文献速递脑血管病

中性粒细胞CD177表达预测人类缺血性卒中结局

CD177 Expression on Neutrophils Predicts Ischemic Stroke Outcome in Humans.
PubMed 文献 · Stroke · 2026-02-26

该研究在PROSCIS-B和NOFF-S两个前瞻性队列中评估CD177null基因型及CD177表达水平对缺血性卒中严重程度和1年或3个月结局的影响。CD177null患者不良结局风险显著升高,且CD177表达水平可改善结局预测。

要点

  • CD177null基因型患者不良卒中结局风险显著高于CD177WT患者。
  • CD177high中性粒细胞比例预测3个月良好临床结局。
  • CD177表达水平可改善卒中结局的预测区分度。

核心结论

  • 入院时CD177表达是易于测量的生物标志物,可用于患者分层。
  • CD177有潜力作为调节卒中后免疫反应的治疗靶点。

研究设计与样本

  • 两项前瞻性队列研究:PROSCIS-B(n=579,平均年龄68.1岁,女性38.5%)和NOFF-S(n=236,平均年龄68.4岁,女性36.9%)。
  • 评估CD177null与CD177WT状态对卒中严重程度(NIHSS)和结局(mRS)的影响,随访1年或3个月。
  • 通过流式细胞术将CD177表达水平分为CD177neg、CD177dim和CD177high。
  • 采用多变量回归和区分度分析评估CD177状态的预测价值。

主要发现

  • PROSCIS-B中CD177null患者26例(4.5%),NOFF-S中10例(4.2%)。
  • CD177null患者不良结局(mRS 3-6)概率高于CD177WT患者:PROSCIS-B中38.1% vs 19.5%(P=0.05),NOFF-S中80.0% vs 16.2%(P<0.0001)。
  • 调整年龄、性别、基线NIHSS、TOAST分型和再灌注治疗后关联仍存在:NOFF-S中相对风险3.8(95% CI 2.0-7.1),P<0.001。
  • NOFF-S中入院时CD177dim中性粒细胞比例与入院卒中严重程度负相关,CD177high比例预测3个月良好临床结局。
  • CD177表达水平在AUC、NRI和IDI分析中显著改善卒中结局预测(CD177high的P值分别为0.004、0.001和P<0.001)。

临床怎么用

  • 入院时检测中性粒细胞CD177表达水平有助于卒中患者风险分层。
  • CD177null基因型患者可能需要更密切监测和积极干预。
  • CD177high比例可作为预测3个月良好结局的参考指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neutrophil granulocytes actively contribute to tissue damage after ischemic stroke. The membrane protein CD (cluster of differentiation)177 is detectable on variable neutrophil numbers in most individuals (CD177 wild-type [CD177WT] genotype), whereas ≈5% of the general population completely lack CD177 (CD177-deficient [CD177null] genotype). Despite its known relevance in vasculitis, the role of ischemic stroke remains unknown. METHODS: In 2 prospective cohorts of patients with first-ever ischemic stroke (PROSCIS-B [Prospective Cohort With Incident Stroke Berlin], NOFF-S [Neutrophils: Origin, Fate & Function Stroke]), we assessed the effect of CD177null and CD177WT status on stroke severity and outcome (National Institutes of Health Stroke Scale and modified Rankin Scale) over 1 year or 3 months poststroke, respectively. By flow cytometry, we stratified CD177 expression level as CD177neg, CD177dim, and CD177high. The predictive value of the CD177 state was evaluated by multivariable regression and discrimination analyses. RESULTS: In PROSCIS-B (n=579; mean age, 68.1 years; 38.5% women) and NOFF-S (n=236, 68.4 years, 36.9% women), similar rates of patients were CD177null (n=26 [4.5%] and n=10 [4.2%], respectively). Patients with CD177null had a higher probability of unfavorable stroke outcome (modified Rankin Scale score 3-6) than patients with CD177WT (n=8 of 21 [38.1%] versus 90 of 462 [19.5%] with follow-up, P=0.05, in PROSCIS-B; n=8 of 10 [80.0%] versus n=23 of 142 [16.2%] with follow-up, P<0.0001, in NOFF-S). This association remained when adjusted for age, sex, initial stroke severity defined by National Institutes of Health Stroke Scale score, stroke subtype defined by TOAST (Trial of ORG 10172 in Acute Stroke Treatment), and reperfusion treatment (relative risk, 3.8 [95% CI, 2.0-7.1]; P<0.001, in NOFF-S). In NOFF-S, the proportion of CD177dim neutrophils at admission was negatively associated with stroke severity at admission, while that of CD177high neutrophils predicted a favorable clinical outcome after 3 months. CD177 expression level significantly improved the prediction of stroke outcome in addition to clinical adjustment variables in area under the curve, net reclassification improvement, and integrated discrimination improvement analyses (P=0.004, P=0.001, and P<0.001, respectively, for CD177high). CONCLUSIONS: CD177 expression at admission is an easy-to-measure biomarker for patient stratification. CD177 holds potential as a therapeutic target to modulate immune responses after stroke. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT01363856. URL: https://drks.de/search/en/trial/Unique identifier: DRKS00030825.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Gronewold J, Hagemann N, Zhang Y, et al. CD177 Expression on Neutrophils Predicts Ischemic Stroke Outcome in Humans. Stroke. 2026. PMID: 41744081. doi:10.1161/STROKEAHA.125.054673

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。